ArticleFrontiers in neurology2025
From demyelination to neurodegeneration in multiple sclerosis: reassessing the role of visual evoked potential P100-N145 amplitudes: a missing piece of the puzzle?
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- VEP Abnormalities in Treatment-Naïve CIS/Early RRMS Without Prior Optic Neuritis: Clinical, Radiological, and CSF Associations.Medicina (Kaunas, Lithuania) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multiple sclerosis (MS) is a chronic demyelinating disease with a heterogeneous clinical course, making long-term disability prediction challenging. Visual evoked potentials (VEPs), particularly amplitude-based parameters, may serve as sensitive biomarkers of neurodegeneration and functional decline undetected by conventional clinical measures. Objective: To assess the relationship between longitudinal changes in P100-N145 amplitude and concurrent Expanded Disability Status Scale (EDSS) changes in relapsing-remitting MS (RRMS) and the relative utility of baseline and longitudinal VEP parameters in representing disability status. Methods: In this retrospective cohort study, 45 MS patients (90 eyes) with available VEP and EDSS data were followed for a median period of 48 months. The primary endpoints were (1) change in EDSS score over time and (2) EDSS progression, defined as any increase in EDSS score from baseline to follow-up. Generalized estimating equations (GEE) and logistic regression were used to investigate the relationships between the VEP parameters at baseline and follow-up and EDSS progression, accounting for inter-eye correlation; partial correlation analysis assessed amplitude-EDSS change associations, controlling for age. Results: EDSS progression was observed in 17.8% of patients. A longitudinal decrease in P100-N145 amplitude from baseline to follow-up was significantly associated with EDSS progression (OR: 1.511, 95% CI, Conclusion: Our results demonstrate that a reduction in P100-N145 amplitude over time is associated with worsening disability in RRMS. This suggests that the P100-N145 may be an underestimated marker of progressive functional deterioration in RRMS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.